BioSpace News Archive

Surrozen, Inc. announced publication of data in eLife highlighting the potential to enhance Wnt-signal activation in new targeted SWEETS bispecific antibodies which utilize a unique protein degradation platform that provides alternatives for future clinical applications.

Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced upcoming presentations at the 2nd Annual Obesity & Weight Loss Drug Development Summit and the 5th Annual RNA Editing Summit, both taking place in Boston on June 11-13 and June 18-20, respectively.

Cranbury Pharmaceuticals (Cranbury), a wholly-owned subsidiary of Tris Pharma, today announced the U.S. Food and Drug Administration (FDA) approved the Abbreviated New Drug Application (ANDA) for the first generic version of Emflaza® oral suspension (deflazacort) for the treatment of Duchenne muscular dystrophy (DMD).

Belite Bio, Inc announces that its lead pipeline, Tinlarebant, has been granted Sakigake Designation by the Ministry of Health, Labour and Welfare in Japan for the treatment of STGD1.

Biophytis SA, a clinical-stage biotechnology company specialized in the development of therapeutics for age-related diseases, announces the successful transfer of BIO101 production to industrial scale by Seqens.

OBI Pharma, a clinical-stage oncology company, announced the initiation of a Phase 1/2 clinical trial of OBI-992, an antibody-drug conjugate targeting TROP2, an antigen overexpressed in multiple tumor types.

Dianthus Therapeutics, Inc. announced U.S. Food and Drug Administration clearance of its Phase 2 Investigational New Drug application for the MoMeNtum trial of DNTH103 in patients with Multifocal Motor Neuropathy.

Affimed N.V., a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, reported financial results and provided an update on clinical and corporate progress for the quarter ended March 31, 2024.

Clearside Biomedical, Inc. announced that multiple oral presentations were delivered at the Clinical Trials at the Summit Meeting on June 8, 2024 in Park City, Utah.

Omeza®, a regenerative skincare company that develops marine-based therapies for nonhealing wounds that are hard to treat, presented three case studies showing that diabetic foot ulcers treated weekly with Omeza® OCM™ demonstrated 90 to 100 percent wound closure at 12 weeks.